TRANSFORMING CLINICAL AND TRANSLATIONAL RESEARCH AND EDUCATION AT ROCKEFELLER

本分项目是CTSA供资的估计百分比，即 被用于广泛的研究领域(艾滋病研究、儿科研究或 临床试验)。列出的总成本仅是对CTSA金额的估计 用于这一研究领域的基础设施，而不是由 授予子项目或子项目工作人员的NCRR补助金。 洛克菲勒大学医院自1963年以来一直是GCRC的获奖者，自1910年以来一直是洛克菲勒临床和转化科学的“家”。它是许多具有里程碑意义的科学和临床贡献的场所，它的许多受训人员后来成为了学术领袖。使用 在临床和翻译科学奖(CTSA)下可用的新资源，CTSA是。杰出的研究人员，他们的研究跨越基础-翻译光谱，涵盖广泛的科学和医学学科，将整合和扩大他们的科学和教育 一个新的洛克菲勒大学临床和翻译科学中心的项目。新的中心将通过鼓励新的研究，并通过加强和集中所需的支持结构，以科学的严谨性和绝对承诺进行研究，来改变临床和转化性研究 保护人体主体和参与者安全。转变中的关键要素将是：1)反映美国国立卫生研究院合作协议(U54)“援助”机制的新治理结构；2)创建新的K-12临床研究学者计划，提供硕士和博士学位，以补充 目前的临床学者计划，3)基础设施增强，以促进良好临床实践(GCP)原则下临床方案的开发和实施，包括生物医学信息学、生物统计学。生物营养、研究护理、研究药房、参与者招募和社区参与，以及临床研究(研究对象)的监管支持和监督 倡导)支持办公室，4)开发与树突状细胞治疗、丙型肝炎和恶性肿瘤、遗传学/基因组学、评估免疫反应和代谢表型有关的创新和新的核心方法。该中心将延续洛克菲勒专注于 科学发现、人类病理生理学和新的诊断、预防和治疗策略之间的接口。在互惠互利的情况下，它将与业界合作，以实现这些目标。该中心也将是国家CTSA联盟的积极成员，为联盟提供新的想法 以及用于进行和评估临床和转化性研究的工具。它还将热切地采用该联盟确定的最佳做法，并遵守该联盟制定的标准。

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. The Rockefeller University Hospital, a GCRC awardee since 1963, has been the continuous "home" for clinical and translational science at Rockefeller since 1910. It has been the site of numerous landmark scientific and clinical contributions, and many of its trainees have gone on to become academic leaders. With the new resources available under a Clinical and Translational Science Award (CTSA), a core faculty of. distinguished investigators, whose research spans the basic-translational spectrum and encompasses a broad range of scientific and medical disciplines, will integrate and expand their scientific and educational programs in a new Rockefeller University Center for Clinical and Translational Science. The new Center will transform clinical and translational research by encouraging new studies, and by enhancing and centralizing the support structures required to conduct studies with scientific rigor and an absolute commitment to protection of human subjects and participant safety. The key elements in the transformation will be: 1) A new governance structure reflecting the NIH cooperative agreement (U54) "assistance" mechanism, 2) Creation of a new K-12 Clinical Research Scholars Program offering Masters and PhD level degrees to complement the current Clinical Scholars,Program, 3) Infrastructure enhancements to facilitate the development and conduct of clinical protocols under the principle of Good Clinical Practice (GCP), including biomedical informatics, biostatistics. bionutrition, research nursing, research pharmacy, participant recruitment and community engagement, and regulatory support and oversight from the clinical research (research subject advocate) support office, 4) Development of innovative and novel core methodologies related to dendritic cell therapy; hepatitis C, and malignancies; genetics/genomics; assessing the immune response; and metabolic phenotyping. The Center will continue Rockefeller's tradition of focusing on the interface between scientific discovery, human pathophysiology, and novel diagnostic, preventive and therapeutic strategies. It will partner with industry, when mutually beneficial, to achieve these goals. The Center will also be an active member of the National CTSA Consortium, offering the Consortium novel ideas and tools for conducting and evaluating clinical and translational research. It will also eagerly adopt the best practices identified by the Consortium and adhere to the standards set by the Consortium.